Key result
Nifedipine SR-candesartan shows no significant blood pressure control benefit over amlodipine-ramipril despite better cost-effectiveness.
Why the study?
Hypertension is a leading cause of mortality and morbidity in Indonesia, requiring long-term therapy, but cost-effectiveness data comparing nifedipine SR-candesartan and amlodipine-ramipril combinations are lacking.
Does the nifedipine SR-candesartan combination improve cost-effectiveness and blood pressure control compared to amlodipine-ramipril in outpatients with hypertension?
Cross-Sectional (n=86)
No
Does the nifedipine SR-candesartan combination improve cost-effectiveness and blood pressure control compared to amlodipine-ramipril in outpatients with hypertension?
The combination of nifedipine SR and candesartan offers a highly cost-effective treatment alternative for hypertension management that simultaneously yields notable improvements in patient quality of life.
Answers are grounded in this paper and cite their sources.
Nifedipine SR-candesartan may offer cost-effective hypertension management with higher utility; leaves open BP control confirmation in randomized trials.
Hypertension is one of the main causes of mortality and morbidity in Indonesia and generally occurs asymptomatic and thus frequently referred to as the silent killer. Long-term therapy is essential, as uncontrolled hypertension can worsen the health and economic status of those affected. First-line therapies recommended by the Joint National Committee’s Eighth Report (JNC 8) include thiazide diuretics, Angiotensin-Converting Enzyme (ACE) inhibitors, Angiotensin II Receptor Blockers (ARBs), and Calcium Channel Blockers (CCBs). The aim of this study was to analyze cost-effectiveness nifedipine sustained release-candesartan compared to amlodipine-ramipril in hypertensive patients. This study was a cross-sectional with primary data obtained from medical records and structured questionnaires prospectively for utility value and adherence level. Total sample of eighty-six outpatients with hypertension fulfill inclusion and exclusion criteria and based on analysis showed that intervention (43 patients) and comparator (43 patients) groups are matching. The results showed that the efficacy of achieving blood pressure control with the nifedipine SR-candesartan combination, as per JNC 8 guidelines, was 48.8% with an Average Cost Effectiveness (ACER) of IDR 6,374. In comparison, the amlodipine-ramipril combination achieved an efficacy of 34.9% with an ACER of IDR 7,421 (p=0.19). The utility gained by patients in the intervention group was higher compared to the comparator group (p=0.004). Hence, it can be concluded that the nifedipine SR-candesartan combination is more cost-effective compared to the amlodipine-ramipril combination.
No takes yet. Share an insight, caveat, or question.
Nabilah et al. (2026) conducted a cross-sectional in Hypertension (n=86). Nifedipine SR-candesartan combination vs. Amlodipine-ramipril combination was evaluated on Target blood pressure achievement (blood pressure control) (RR 0.7, 95% CI 0.5-1.1, p=0.19). The nifedipine SR-candesartan combination achieved blood pressure control in 48.8% of patients compared to 34.9% for amlodipine-ramipril (p=0.19), demonstrating a more favorable cost-effectiveness ratio.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: